Background: Guidance addressing atopic dermatitis (AD) management, last issued in 2012 by the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force, requires updating as a result of new treatments and improved guideline and evidence synthesis methodology.

Objective: To produce evidence-based guidelines that support patients, clinicians, and other decision-makers in the optimal treatment of AD.

Conclusion: These evidence-based recommendations address optimal use of (1) topical treatments (barrier moisturization devices, corticosteroids, calcineurin inhibitors, PDE4 inhibitors [crisaborole], topical JAK inhibitors, occlusive [wet wrap] therapy, adjunctive antimicrobials, application frequency, maintenance therapy), (2) dilute bleach baths, (3) dietary avoidance/elimination, (4) allergen immunotherapy, and (5) systemic treatments (biologics/monoclonal antibodies, small molecule immunosuppressants [cyclosporine, methotrexate, azathioprine, mycophenolate, JAK inhibitors], and systemic corticosteroids) and UV phototherapy (light therapy).

背景：2012年由美国过敏、哮喘和免疫学会/美国过敏、哮喘和免疫学会联合工作组最新发布的特应性皮炎(AD)管理指南，需要更新新的治疗方法以及改进的指南和证据综合方法。

目的：制定循证指南，支持患者、临床医生和其他决策者针对AD进行最佳治疗。

结论：这些基于证据的建议解决了以下最佳使用问题：(1) 局部治疗（屏障保湿设备、皮质类固醇、钙调磷酸酶抑制剂、PDE4抑制剂[克立硼罗]、局部JAK抑制剂、封闭性[湿性包裹]治疗、辅助抗菌剂、用药频率、维持治疗）；(2) 稀漂白液；(3) 饮食回避/消除；(4) 过敏原免疫治疗；(5) 全身性治疗（生物制剂/单克隆抗体、小分子免疫抑制剂 [环孢素、甲氨蝶呤、硫唑嘌呤、麦考酚酯、JAK抑制剂] 和全身性皮质类固醇）和UV光疗（光照疗法）。